NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus [ID1203]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following potential equality issues were raised during draft scope consultation and the scoping workshop discussion:

- **Availability of HLA phenotypes for ethnic mix in NHS clinical practice** - tabelecleucel is selected for each patient from a US inventory based on an EBV HLA-restricting allele and a second shared allele. The clinical experts at the scoping workshop raised that it was unclear whether the coverage of HLA phenotypes in this inventory would cover the range needed for the ethnic mix of the population in NHS clinical practice

- **Eligibility for previous treatments** – age and frailty may mean that some people are not fit enough to have rituximab (R) with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone). The population eligible for tabelecleucel is previously treated EBV+ PTLD, and one of the previous treatments is R-CHOP

- **Religious beliefs** – tabelecleucel is a T-cell product and therefore tabelecleucel may be an unacceptable treatment option for people with some religious beliefs, for example Jehovah's Witnesses.

2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- **Availability of HLA phenotypes for ethnic mix in NHS clinical practice** – the company have agreed to include further information on ethnic mix included in the tabelecleucel inventory and comparability with the ethnic mix in NHS clinical practice in their submission. This issue will be fully considered by the committee

- **Eligibility for previous treatments** – It is expected that the marketing authorisation will specify that people should have had previous treatment, and NICE can only make recommendation withing a technology's marketing authorisation. However, the potential for some people to be ineligible for specific previous treatments due to age or frailty will be fully considered by the committee in formulating its recommendations

- **Religious beliefs** – any positive recommendation for tabelecleucel will state that it is an option, if it is considered an appropriate treatment by patients and their clinicians.

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No. It is expected that the patient and carer organisations currently included on the stakeholder list will be able to provide the relevant insight into the equality issues highlighted.	

Approved by Associate Director (name): Ross Dent
Date: 22/08/2022